Meeting
2018 ASCO Annual Meeting
Neoadjuvant chemo/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study—NADIM study-SLCG.
Authors
Mariano Provencio-Pulla
Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
Mariano Provencio-Pulla , Ernest Nadal-Alforja , Manuel Cobo , Amelia Insa , Marinha Costa Rivas , Margarita Majem , Delvys Rodriguez-Abreu , Guillermo Lopez-Vivanco , Manuel Domine , Elvira Del Barco Morillo , Bartomeu Massuti , Rosario Garcia Campelo , Alexandre Martinez Marti , Reyes Bernabé , Fernando Franco , Maria Jove , Ricardo Arrabal , Paloma Martin , Joaquin Casal , Virginia Calvo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT03081689
Citation
J Clin Oncol 36, 2018 (suppl; abstr 8521)
DOI
10.1200/JCO.2018.36.15_suppl.8521
Abstract #
8521
Poster Bd #
127
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Peripheral blood T-cell receptor immune repertoire characterization of resectable stage IIIA non-small cell lung cancer patients receiving neo-adjuvant chemo-immunotherapy treatment from NADIM study.
First Author: Alberto Cruz Bermudez
Poster
2019 ASCO Annual Meeting
NEO-adjuvant chemo-immunotherapy for the treatment of STAGE IIIA resectable non-small-cell lung cancer (NSCLC): A phase II multicenter exploratory study—Final data of patients who underwent surgical assessment.
First Author: Mariano Provencio
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Assessment of complete pathologic response after neoadjuvant immunotherapy for MSI-H gastrointestinal cancers.
First Author: Kruti Bhagirath Vora
Poster
2020 ASCO Virtual Scientific Program
CT and PET radiomic features associated with major pathologic response to neoadjuvant immunotherapy in early-stage non-small cell lung cancer (NSCLC).
First Author: Erica C. Nakajima